lorazepam has been researched along with Premenstrual Syndrome in 2 studies
Lorazepam: A benzodiazepine used as an anti-anxiety agent with few side effects. It also has hypnotic, anticonvulsant, and considerable sedative properties and has been proposed as a preanesthetic agent.
Premenstrual Syndrome: A combination of distressing physical, psychologic, or behavioral changes that occur during the luteal phase of the menstrual cycle. Symptoms of PMS are diverse (such as pain, water-retention, anxiety, cravings, and depression) and they diminish markedly 2 or 3 days after the initiation of menses.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, J | 1 |
| Zitron, E | 1 |
| Katus, HA | 1 |
| Becker, R | 1 |
| Smith, SS | 1 |
| Gong, QH | 1 |
| Hsu, FC | 1 |
| Markowitz, RS | 1 |
| ffrench-Mullen, JM | 1 |
| Li, X | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Dienogest Versus Luteal Phase Fluoxetine in the Management of Premenstrual Syndrome: A Randomized Double Blind Placebo Controlled Trial[NCT02427334] | Phase 3 | 210 participants (Anticipated) | Interventional | 2015-04-30 | Recruiting | ||
| The Synergistic Use of Combined Oral Contraceptives and Fluoxetine Versus Combined Oral Contraceptives in the Management of Severe Premenstrual Syndrome: A Randomized Double Blind Placebo Controlled Trial[NCT02488538] | Phase 3 | 300 participants (Anticipated) | Interventional | 2015-07-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 other studies available for lorazepam and Premenstrual Syndrome
| Article | Year |
|---|---|
PMS: premenstrual storm? An unusual cause of electrical storm in a young woman with vasospastic angina.
Topics: Adult; Amiodarone; Angina Pectoris, Variant; Biomarkers; Defibrillators, Implantable; Diltiazem; Dru | 2011 |
GABA(A) receptor alpha4 subunit suppression prevents withdrawal properties of an endogenous steroid.
Topics: Animals; Anti-Anxiety Agents; Azides; Benzodiazepines; Carbolines; Female; gamma-Aminobutyric Acid; | 1998 |
GABA(A) receptor alpha4 subunit suppression prevents withdrawal properties of an endogenous steroid.
Topics: Animals; Anti-Anxiety Agents; Azides; Benzodiazepines; Carbolines; Female; gamma-Aminobutyric Acid; | 1998 |
GABA(A) receptor alpha4 subunit suppression prevents withdrawal properties of an endogenous steroid.
Topics: Animals; Anti-Anxiety Agents; Azides; Benzodiazepines; Carbolines; Female; gamma-Aminobutyric Acid; | 1998 |
GABA(A) receptor alpha4 subunit suppression prevents withdrawal properties of an endogenous steroid.
Topics: Animals; Anti-Anxiety Agents; Azides; Benzodiazepines; Carbolines; Female; gamma-Aminobutyric Acid; | 1998 |